Live Breaking News & Updates on Dee datta

Stay informed with the latest breaking news from Dee datta on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Dee datta and stay connected to the pulse of your community

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

SOUTH SAN FRANCISCO, Calif., January 03, 2024--Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

South-san-francisco , California , United-states , South-korea , Han , Dtx-pharma , Tressa-frankel , Dee-datta , Charles-allerson , National-institutes-of-health , Harvard-university , Linkedin

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

BioPharma

William-blair , Athira-pharma , Kevin-eisele , Novo-nordisk-ozempic , Eli-lilly-mounjaro , Dee-datta , Edward-kaye , Andrew-gengos , Nasdaq , Biopharma-dive-wednesday , Jordan-saxe , Switch-therapeutics

Switch Therapeutics launches with $52M to capitalize on RNA medicine 'era'

BioPharma

California , United-states , California-institute-of-technology , South-korea , South-san-francisco , Han , Dee-datta , Eli-lilly , Alnylam-pharmaceuticals , Arrowhead-pharmaceuticals , Dicerna-pharmaceuticals , Ionis-pharmaceuticals

Switch Therapeutics Raises $52M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

South-korea , Han , Dee-datta , Eli-lilly , Harvard-medical-school , Switch-therapeutics , South-san-francisco , Insight-partners , Upfront-ventures , Ono-venture-investment , Digitalis-ventures , Dolby-family-ventures

Switch Therapeutics Comes Out of Stealth to Advance First-of-its-Kind RNAi Technology

Switch Therapeutics announced $52M in early funding to develop conditionally activated small interfering (CASi) RNA therapeutics.

South-korea , Han , Wilson-hill , Lisa-scherer , Eli-lilly , Alicia-irurzun , Bill-goddard , Dee-datta , Saumya-das , John-rossi , Astrazeneca , Switch-therapeutics